The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
about
The clinical implications of gene mutations in chronic lymphocytic leukaemiaClinical implications of the molecular genetics of chronic lymphocytic leukemiaThe biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaMutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyMutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.Clinical outcomes and correlates of TP53 mutations and cancer.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessBiologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationTumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.Telomere status in chronic lymphocytic leukemia with TP53 disruption.Molecular pathogenesis of chronic lymphocytic leukemia.Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.The spectrum of genetic defects in chronic lymphocytic leukemia.Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia.
P2860
Q26749214-464F7F69-9B04-4318-A42D-2301EB9E959EQ26830955-AF37E7BA-F40E-4422-AD00-5BC9C3329C5FQ27024411-E4972665-F33F-40DE-881B-72576F42F5E0Q27851685-80CB1D81-A8E5-40AF-9CCB-354EFA70CC42Q28077136-121C6B4F-1618-4CFC-A0A0-835C29380064Q29013141-9A6B7CC2-4003-4B6A-B658-FED54F85BDAAQ30365539-DB0CBECF-2A3D-46D4-A2B9-C7C79CD687CCQ33396594-75DA4A78-8E05-41A8-83BF-1FD80909DDF2Q33409459-4E2D2990-28BD-4E72-A6C5-F637ADEB174BQ33558740-F7BC4BE4-E06A-4A7C-91F9-7AC4ECE57806Q33595764-E904F187-E7A4-4F1C-946D-102E21CF1632Q33693838-55634ACD-AAC6-426A-B489-74F300283393Q33709543-99AFA287-C74F-4BD2-8E5D-023048A0D564Q33886052-1C92A884-0856-42D1-8060-6845838D6FB7Q33978930-14290F12-D1A0-4CA7-BABB-E73364DEDE76Q34166551-79F70320-4885-4EC9-BFFF-D95724918C93Q34453174-229ECE14-D87E-4AA6-ADC3-886C84E46394Q34461989-52C7100F-A2A1-4E54-AD30-EE33F6942D84Q35049753-2CBF90F9-0B7E-4D59-A164-A951F515B8D2Q35149661-7D25DA49-5D2A-42E3-A755-8D0AC14F8C13Q35220403-E3815017-3008-46F9-A892-2FA1164E3136Q35407650-5D1DF177-5F78-42AC-8C21-27E0B0A9D187Q35597328-5CE43FB2-ACF2-44A8-A7E3-BEBB75A0EFA7Q35643026-D0608F32-4C6E-4C24-81A1-9D802B2C5702Q35859176-39593119-83C2-425B-A9A3-2FE182652A2FQ36093789-B1657142-0229-493E-8E54-4659BFF8DAD5Q36290321-FCFAB48B-02C1-4C4C-AD5E-BE26648F4886Q36420752-CDBBB8E7-8CA1-40A7-AFD5-F5E9F8515367Q36426587-558B8458-6352-4359-81F8-C11EF91AE7B4Q36597026-0FA964E0-8973-4F83-90EC-48ECD4AE8E84Q36826893-951CE86B-6732-4E5E-A4BC-9263410BD903Q37049035-E01B97AB-4FDD-4F8A-BDD6-F12BA9A25B68Q37326100-E6C78A58-9F8B-4434-BCBA-4B1874679B78Q37429218-B98517ED-533B-460D-8509-7FAFCBDB748FQ37434174-0E74015E-2133-4E53-B74F-FAD457B0B1ACQ37532952-4EC710A1-2987-43BE-A974-BEC079B4B0F1Q37588785-5D9322A4-3205-4AF3-9F2F-D686C69B0531Q37616347-260156DC-9799-43E9-BC74-6869EF595907Q37618663-430F211C-0938-4781-B31A-983B36277967Q37694914-5063627A-8B3D-4AB1-ABC1-DB2E32858F61
P2860
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@en
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@nl
type
label
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@en
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@nl
prefLabel
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@en
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@nl
P2093
P50
P1476
The prognostic value of TP53 m ...... vival and chemorefractoriness.
@en
P2093
Clara Deambrogi
Davide Rossi
Elisa Sozzi
Francesco Lauria
Michaela Cerri
Silvia Rasi
Stefania Cresta
Valeria Spina
P304
P356
10.1158/1078-0432.CCR-08-1630
P407
P577
2009-02-01T00:00:00Z